Edoxaban/Antiplatelets; Aspirin (Greater Than 100 mg) Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
All of these medicines can affect your blood's ability to clot.
What might happen:
Taking these medicines together or within a short time of each other may increase your risk of bleeding, including bleeding from your gums, nosebleeds, unusual bruising, or dark stools.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together.Let your doctor know right away if you have any bleeding episodes or signs of bleeding.If your doctor is changing you from one anticoagulant to another, be sure to follow any special instructions you receive about this change.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Savaysa (edoxaban) US prescribing information. Daiichi Sankyo, Inc August, 2019.
- 2.Lixiana (edoxaban tosilate) UK summary of product characteristics. Daiichi Sankyo UK Limited July 2, 2015.
- 3.Lixiana (edoxaban) Canadian product monograph. Servier Canada Inc. January 12, 2017.
- 4.FDA Center for Drug Evaluation and Research (CDER). Application number 206316 Savaysa (edoxaban tosylate) Clinical Pharmacology and Biopharmaceutics Review. available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206316Orig1Orig2s00 0ClinPharmR.pdf January 8, 2015.
- 5.Valeriani E, Porreca E, Weitz JI, Schulman S, Candeloro M, Di Nisio M. Impact of concomitant antiplatelet therapy on the efficacy and safety of direct oral anticoagulants for acute venous thromboembolism: Systematic review and meta-analysis. J Thromb Haemost 2020 Jul;18(7):1661-1671.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.